Skip to main content

Table 1 Drug concentration leading to a 50% inhibition of cell viability at 72 h (IC50) in cellTiterGLO® assay and Combination Index (CI) for each cell line

From: The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma

MPM Cell Lines IC50 Drug alone (95% confidence interval) IC50 Drug combination (95% confidence interval) CI at IC50 ± Est. st.dev*
Everolimus (nM) Sorafenib (μM) Everolimus (nM) Sorafenib (μM)
MES-MM98 >100 4.21 (2.91-6.09) 40 (10.6-150.5) 2 (1.03-4.02) 0.485 ± 0.20
MM001 >100 2.01 (1.86-2.21) 23.6 (14.9-37.5) 1.18 (0.75-1.87) 0.585 ± 0.08
NCI-H226 >100 2.12 (1.55-2.89) 32 (20.5-49.9) 1.60 (1.02-2.49) 0.755 ± 0.23
MSTO-211H >100 0.90 (0.68-1.19) 34 (33.4-35.3) 0.17 (0.01-1.77) 0.426 ± 0.19
IST-MES1 >100 1.69 (1.10-2.60) 28.3 (17.1-46.8) 1.42 (0.85-2.34) 0.873 ± 0.30
IST-MES2 >100 2.16 (1.66-2.80) 19.1 (9.8-37.1) 0.96 (0.49-1.86) 0.573 ± 0.22
NCI-H28 >100 3.34 (2.27-4.92) 27 (14–51.6) 1.36 (0.71-2.58) 0.920 ± 0.34
NCI-H2052 >100 6.21 (4.45-8.66) 44.7 (31–63.9) 2.23 (1.56-3.19) 0.950 ± 0.21
MM002 >100 2.78 (2.30-3.35) 18.6 (6–57.2) 0.93 (0.30-2.86) 0.345 ± 0.12
  1. *combination index calculated at IC50 ± estimated standard deviation based on Chou-Talalay method.